Gilead Sciences (GILD) said Wednesday that it has signed non-exclusive, royalty-free voluntary licensing deals with six pharmaceutical companies to manufacture and sell generic lenacapavir for the prevention of HIV in 120 mostly low-income countries.
The pharmaceutical companies include Dr. Reddy's Laboratories (RDY), Emcure, Eva Pharma, Ferozsons Laboratories, Hetero Drugs, and Viatris (VTRS) subsidiary Myla.
Gilead said it plans to price the product at no profit to the company.
The company also said the six licensees will build manufacturing capacity for lenacapavir "as quickly as possible."
Price: 83.70, Change: -0.24, Percent Change: -0.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.